Clinical Trial News and Research

RSS

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

The nanopharmaceutical drug CRLX101 is showing promise as a potential new treatment for cancers that develop resistance to antiangiogenic drugs and radiation therapy, according to clinical trial results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19 - 23.

22 Oct 2013

Two drug combinations may provide new treatment option for patients with pancreatic cancers

Two drug combinations that simultaneously block two major signaling pathways downstream of the protein KRAS, which is aberrantly active in most pancreatic cancers, may provide a new treatment option for patients with this disease, according to preclinical results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held Oct. 19-23.

22 Oct 2013

Researchers receive NIH grant to conduct Vitamin D and Type 2 diabetes study

A research team led by Anastassios G. Pittas, MD, MS, Endocrinologist and Co-Director of the Diabetes Center at Tufts Medical Center in Boston, has received a National Institutes of Health grant of more than $40 million over five years to conduct the Vitamin D and Type 2 diabetes study.

22 Oct 2013

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Olodaterol is a long-acting beta2-agonist (LABA) bronchodilator delivered via the Respimat® inhaler. It is being investigated as a once daily maintenance bronchodilator treatment of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including chronic bronchitis and/or emphysema.

21 Oct 2013

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

Inovio Pharmaceuticals, Inc. announced today that the safety, tolerability and immunogenicity of its therapeutic vaccine for hepatitis C (INO-8000/VGX-6150) will be studied in a phase I clinical trial in chronically HCV infected patients.

21 Oct 2013

DrugDev acquires CFS Clinical

DrugDev, an interactive network and data sharing platform for over 80,000 clinical trial doctors in 93 countries, announced today its acquisition of CFS Clinical (CFS), the leading specialty provider focused on the business and financial management activities for clinical trials.

21 Oct 2013

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

LEE011, a small-molecule inhibitor of cyclin-dependent kinases (CDK) 4/6 being developed by Novartis Oncology, showed promising results in drug-resistant melanoma and drug-resistant breast cancer when tested in combination with other targeted therapies, and based on these preclinical results, several phase I clinical trials were launched recently, according to results presented here at the AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, held October 19-23.

21 Oct 2013

Research Institute receives Fast Track status for its gene therapy product for treatment of SMA

AveXis and BioLife, synthetic biology platform companies, today announced that The Research Institute at Nationwide Children's Hospital received Fast Track designation from the U.S. Food and Drug Administration for its scAAV9.CB.SMN gene therapy product for the treatment of spinal muscular atrophy (SMA).

19 Oct 2013

Alimera Sciences receives Complete Response Letter for New Drug Application from FDA

Alimera Sciences, Inc., a biopharmaceutical company that specializes in the research, development and commercialization of prescription ophthalmic pharmaceuticals, today announced that it has received a Complete Response Letter (CRL) for the New Drug Application (NDA) for ILUVIEN® from the U.S. Food and Drug Administration (FDA).

19 Oct 2013

Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

The Intellectual Property & Science business of Thomson Reuters, the world's leading provider of intelligent information for businesses and professionals, today announced the addition of Clinical Trials Intelligence to the Thomson Reuters CortellisTM suite, the industry's most comprehensive information solution for drug discovery and development.

19 Oct 2013

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

The U.S. Food and Drug Administration today approved Opsumit (macitentan), a new drug to treat adults with pulmonary arterial hypertension (PAH), a chronic, progressive and debilitating disease that can lead to death or the need for lung transplantation.

19 Oct 2013

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

ARIAD Pharmaceuticals, Inc. today announced that it is discontinuing the Phase 3 EPIC (Evaluation of Ponatinib versus Imatinib in Chronic Myeloid Leukemia) trial of Iclusig (ponatinib) in patients with newly diagnosed chronic myeloid leukemia.

18 Oct 2013

pSivida reports that Alimera Sciences gets FDA Complete Response Letter for ILUVIEN NDA

pSivida Corp., a specialty pharmaceutical company that is a leader in developing sustained release drugs for treatment of back-of-the-eye diseases, today announced that its licensee Alimera Sciences, Inc. has received a Complete Response Letter for the New Drug Application for ILUVIEN from the U.S. Food and Drug Administration.

18 Oct 2013

GenSpera to present G-202 Phase I trial in hepatocellular carcinoma at EORTC-NCI-AACR Symposium

GenSpera, Inc. (OTCBB:GNSZ) announced that Devalingam Mahalingam, MD, PhD, principal investigator of the G-202 Phase II trial in hepatocellular carcinoma, will present data from the G-202 Phase I clinical trial at the EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics in Boston, MA on Monday, October 21st.

18 Oct 2013

Two drugs in combination improve survival in patients with advanced pancreatic cancer

Investigators at the Vall d´Hebron University Hospital and the Vall d'Hebron Institute of Oncology (VHIO), have participated in an international phase III study, published in The New England Journal of Medicine.

18 Oct 2013

NEJM publishes Celgene’s Abraxane phase III study results

Published today in the New England Journal of Medicine, a phase III clinical trial of Abraxane (paclitaxel formulated as albumin-bound nanoparticles) in combination with gemcitabine in treatment-naive patients with metastatic pancreatic cancer demonstrated a statistically significant improvement in overall survival compared to patients receiving gemcitabine alone [(median of 8.5 vs. 6.7 months) (HR 0.72, P=0.000015)].

17 Oct 2013

King's College researchers identify new biomarker that detects sepsis in blood

Researchers at King's College London have identified a biomarker - a biological 'fingerprint' - for sepsis in the blood, and showed it could be possible to diagnose the condition within two hours by screening for this biomarker at a patient's bedside.

17 Oct 2013

BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

Mutations in a gene that codes for the enzyme BRAF kinase have been associated with increased risk for papillary thyroid cancer. An early-stage clinical trial of the BRAF inhibitor vemurafenib resulted in either a partial response or stable disease in patients with PTC and BRAF mutations.

17 Oct 2013

Researchers discover why women with BRCA gene develop breast and ovarian cancer

Researchers announced today in the journal Lancet Oncology that they are well on the way to discovering why women with the faulty genes BRCA 1 and BRCA 2, one of which was inherited by the actress Angelina Jolie, develop breast and ovarian cancer rather than other cancers.

17 Oct 2013

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Celgene International Sàrl, a wholly-owned subsidiary of Celgene Corporation , today announced the results of the MPACT phase III clinical trial of ABRAXANE® in combination with gemcitabine were published online in the October 16th edition of the New England Journal of Medicine.

17 Oct 2013

Clinical Trial News and Research

Nanopharmaceutical drug shows promise for cancers that resist antiangiogenic drugs

Two drug combinations may provide new treatment option for patients with pancreatic cancers

Researchers receive NIH grant to conduct Vitamin D and Type 2 diabetes study

COPD investigational treatments: an interview with Dr. Tunde Otulana, Senior Vice President, Clinical Development and Medical Affairs, Boehringer Ingelheim Pharmaceuticals, Inc.

Inovio Pharmaceuticals begins phase I clinical trial for hepatitis C vaccine

DrugDev acquires CFS Clinical

New small-molecule inhibitor shows promising results in drug-resistant melanoma, breast cancer

Research Institute receives Fast Track status for its gene therapy product for treatment of SMA

Alimera Sciences receives Complete Response Letter for New Drug Application from FDA

Thomson Reuters adds Cortellis Clinical Trials Intelligence for drug discovery and development

Opsumit drug receives FDA approval to treat adults with pulmonary arterial hypertension

ARIAD discontinues Phase 3 EPIC trial of Iclusig in patients with chronic myeloid leukemia

pSivida reports that Alimera Sciences gets FDA Complete Response Letter for ILUVIEN NDA

GenSpera to present G-202 Phase I trial in hepatocellular carcinoma at EORTC-NCI-AACR Symposium

Two drugs in combination improve survival in patients with advanced pancreatic cancer

NEJM publishes Celgene’s Abraxane phase III study results

King's College researchers identify new biomarker that detects sepsis in blood

BRAF inhibitor vemurafenib effective for patients with papillary thyroid cancer

Researchers discover why women with BRCA gene develop breast and ovarian cancer

New England publishes results of phase III clinical trial of ABRAXANE for metastatic pancreatic cancer

Event guide: 15th World Clinical Biomarkers & CDx Europe eBook

Latest eBooks

Industry Focus eBook - Microbiome (1st edition)

Industry Focus eBook - Cell biology (5th edition)

Advancing degrader and proximity-based drug development

Driving innovation in Korean drug development

How ELRIG Is Helping Mid-Career Scientists Navigate Leadership, Career Change and Redundancy

The role of UV-Vis in biopharma QC

Applications Engineer